Table 1.
Incidence rate of ChILI per CPI regime at NUH.
| Cancer | CPI regimen | Total person-time at risk (months) | ChILI cases (n) | IR per 1,000 person-months | 95% CI |
|---|---|---|---|---|---|
| Malignant melanoma | Ipilimumab | 200.5 | 2 | 10.0 | 1.2–36 |
| Ipilimumab + nivolumab followed by nivolumab | 761.1 | 29 | 38.1 | 25.5–54.7 | |
| Nivolumab | 281.2 | 0 | 0 | 0–13.1 | |
| Pembrolizumab | 1,035.4 | 3 | 2.9 | 0.6–8.5 | |
| Adjuvant pembrolizumab | 343.3 | 1 | 2.9 | 0.1–16.2 | |
| Advanced RCC | Ipilimumab + nivolumab followed by nivolumab | 149.1 | 2 | 13.4 | 1.6–48.5 |
| Nivolumab | 524.7 | 1 | 1.9 | 0–10.6 | |
| Total | All regimens | 3,295.3 | 38 | 11.5 | 8.2–15.8 |
The incidence rate of ChILI was estimated by dividing the number of ChILI events in each subgroup by the total person-months at risk, and 95% CI was calculated based on Byar's method. CI, confidence interval; CPI, checkpoint inhibitors; ChILI, checkpoint inhibitor-induced liver injury; IR, incidence rate; RCC, renal cell carcinoma.